PBAC's latest decision on Dutasteride: Not recommended (2009). Considered for treatment of benign prostatic hyperplasia (BPH) in men over 50 years who meet certain criteria.
PBAC outcome
Not recommended
2009
ICER (AUD/QALY)
$45k/QALY
Range: $15k/QALY–$45k/QALY
Submissions
1
first 2009
Submissions
1
2009 → 2009
Eligible population
men over 50 years with symptomatic benign prostatic hyperplasia (BPH) who meet certain criteria
Therapy area
Urology
Evidence base
RCT
Primary endpoint
IPSS score improvement
Key trials
ARI40005
Comparator
prazosin monotherapy
Economic model
CUA
Why PBAC said no
Reasons cited in the latest PSD: uncertain clinical benefit, highly uncertain cost effectiveness, uncertainty in utilities applied to health states in the economic model, practical implementation concerns regarding restriction, small and uncertain clinical significance of IPSS improvement (1.8 point difference)